News
CTR launches podcast together with SwedenBIO
The first episode of the podcast Idé till patient (Idea to patient) will be released on April 12. The podcast series is a co-production between the companies within the CTR-group and SwedenBIO. The series comprises six episodes where invited guests from the pharma...
CTR acquires preclinical toxicology company
Center for Translational Research Sweden AB (CTR) acquires Toxicology Knowledge Team Sweden AB (TKT) further strengthening the CTR group with optimised toxicological support. From April 1, TKT is a fully owned subsidiary to the holding company CTR. The activities at...
New statement of OECD GLP compliance
Happy and proud to share that Lablytica has just received their new statement of OECD GLP compliance for Analytical and Clinical Chemistry testing (8) from SWEDACs inspection on the 10 November 2020....
Karin Meyer blir ny VD för Center for Translational Research Sweden AB (CTR)
CTR tillkännager att styrelsen har utsett Karin Meyer till ny verkställande direktör. Karin Meyer efterträder Mats Lindquist som varit verkställande direktör sedan starten av CTR 2016. Karin Meyer har en lång erfarenhet av ledande befattningar inom läkemedels- och...
David Pekar becomes CEO at Lablytica
Lablytica Life Science AB started in November 2019 when Recipharm’s GLP bioanalysis business was divested to Center for Translational Research AB (CTR). David Pekar has since then been the Site Manager and Chief Scientific Officer at Lablytica. As announced by CTR,...
Recipharm divests bioanalysis business to Center for Translational Research AB further strengthening existing partnership with CTC Clinical Trial Consultants AB
Recipharm, the contract development and manufacturing organisation, and CTC Clinical Trial Consultants have strengthened their partnership with the divestment of Recipharm’s GLP bioanalysis business to the Center for Translational Research AB (CTR) group. CTR is the...